Assessment of the effectiveness and safety of bevacizumab-based therapies for recurrent primary brain tumors: a multicenter real-world study by the Turkish Oncology Group (TOG) - Summary - MDSpire

Assessment of the effectiveness and safety of bevacizumab-based therapies for recurrent primary brain tumors: a multicenter real-world study by the Turkish Oncology Group (TOG)

  • By

  • Zehra Sucuoğlu İşleyen

  • Şaban Seçmeler

  • Abdullah Sakin

  • Şener Cihan

  • Mehmet Beşiroğlu

  • Seda Kahraman

  • Melek Karakurt Eryılmaz

  • Esra Zeynelgil

  • Eda Çalışkan Yıldırım

  • Engin Kut

  • Nilay Şengül

  • Fatma Paksoy Türköz

  • Özkan Alan

  • Özlem Özkul

  • Selver Işık

  • Feride Yılmaz

  • Ahmet Gülmez

  • Sema Türker

  • Gökhan Karakaya

  • Meral Günaldı

  • Leyla Özer

  • Asude Aksoy

  • Fatih Karataş

  • Teoman Sakalar

  • Derya Demirtaş Esmer

  • Fatih Teker

  • Necla Demir

  • Özgecan Dülgar

  • Serdar Turhal

  • Hacı Mehmet Türk

  • Kayhan Ertürk

  • Emir Çelik

  • M. Mustafa Atcı

  • February 14, 2026

  • 0 min

Share

Objective:

To assess the real-world effectiveness and tolerability (safety and side effects) of bevacizumab-based treatment regimens in patients with recurrent primary brain malignancies.

Key Findings:
  • Bevacizumab-based therapies showed variable effectiveness in real-world settings, with specific response rates.
  • Combination therapies with irinotecan demonstrated improved radiological responses, with statistical significance.
  • Adverse events were recorded, highlighting the safety profile of bevacizumab-based regimens, including specific types of adverse events.
Interpretation:

The study indicates that while bevacizumab-based therapies can improve disease control in recurrent primary brain tumors, consistent overall survival benefits remain unproven, necessitating further research.

Limitations:
  • Retrospective design may introduce bias.
  • Lack of standardized treatment protocols across centers.
  • Variability in radiological assessment methods.
  • Potential confounding factors in data collection.
Conclusion:

Bevacizumab-based therapies are a viable option for managing recurrent primary brain tumors, but further studies are needed to establish their long-term efficacy and safety.

Original Source(s)

Assessment of the effectiveness and safety of bevacizumab-based therapies for recurrent primary brain tumors: a multicenter real-world study by the Turkish Oncology Group (TOG)

  • by Zehra Sucuoğlu İşleyen, Şaban Seçmeler, Abdullah Sakin, Şener Cihan, Mehmet Beşiroğlu, Seda Kahraman, Melek Karakurt Eryılmaz, Esra Zeynelgil, Eda Çalışkan Yıldırım, Engin Kut, Nilay Şengül, Fatma Paksoy Türköz, Özkan Alan, Özlem Özkul, Selver Işık, Feride Yılmaz, Ahmet Gülmez, Sema Türker, Gökhan Karakaya, Meral Günaldı, Leyla Özer, Asude Aksoy, Fatih Karataş, Teoman Sakalar, Derya Demirtaş Esmer, Fatih Teker, Necla Demir, Özgecan Dülgar, Serdar Turhal, Hacı Mehmet Türk, Kayhan Ertürk, Emir Çelik, M. Mustafa Atcı

  • February 14, 2026

Related Content

2026 Brain and Spine Symposium Highlights Advances Across the Neurosciences

Over two days, specialists across neurology, neurosurgery and related subspecialties came together to discuss advances in stroke care, epilepsy, movement disorders, neurodegenerative disease, neuro-oncology, brain and spine surgery, interventional pain management and emerging technologies.

  • by

  • May 21, 2026

  • 1 min
CMRA-DETR: A Lightweight and High-Accuracy Detection Framework for MRI-Based Brain Tumor Identification

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.